Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Core Viewpoint - Johnson & Johnson announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, aimed at expanding its U.S. manufacturing capacity and enhancing its portfolio of transformational medicines for cancer and immune-mediated diseases [1] Group 1 - The investment will exceed $1 billion, indicating a significant commitment to advancing cell therapy capabilities [1] - The new facility will contribute to the expansion of Johnson & Johnson's manufacturing capacity in the U.S. [1] - This initiative is part of the company's strategy to enhance its industry-leading portfolio and pipeline of medicines [1]